Leukemia Research
Volume 27, Issue 5 , Pages 387-392 , May 2003

The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases

  • Takuya Fukushima

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
    • ,
  • Yasushi Miyazaki

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-95-849-7111; fax: +81-95-849-7113.
    • ,
  • Hideki Tsushima

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
    • ,
  • Chizuko Tsutsumi

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
    • ,
  • Jun Taguchi

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
    • ,
  • Shinichiro Yoshida

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
    • ,
  • Kazutaka Kuriyama

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan
    • ,
  • David Scadden

      Affiliations

    • MGH Cancer Center and AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Harvard, MA, USA
    • ,
  • Stephen Nimer

      Affiliations

    • Sloan-Kettering Institute for Cancer Research, New York, NY, USA
    • ,
  • Masao Tomonaga

      Affiliations

    • Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan

Received 17 April 2002 ,Accepted 4 September 2002.

References 

  1. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin. Oncol. 1997;24:17
  2. Raimondi SC, Ravindranath Y, Chang MN, Behm FG, Gresik MV, Steuber CP, et al.  Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999;94:3707
  3. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173
  4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322
  5. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700
  6. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al.  Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature. 2000;403:503
  7. Wasylyk B, Hahn SL, Giovane A. The ETS family of transcription factors. Eur. J. Biochem. 1993;211:7
  8. Crepieux P, Coll J, Stehelin D. The ETS family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crit. Rev. Oncog. 1994;5:615
  9. Dittmer J, Nordheim A. ETS transcription factors and human disease. Biochem. Biophys. Acta. 1998;1377:F1–F11
  10. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 1994;6:146
  11. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, et al.  A variant Ewing’s sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995;10:1229
  12. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al.  Gene fusion with an ETS-binding domain caused by chromosome translocation in human tumors. Nature. 1992;359:162
  13. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, et al.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 1995;92:4917
  14. Golub T, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307
  15. Nunn MF, Seeburg PH, Moscovici C, Duesberg PH. Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature. 1983;306:391
  16. Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukemias. Nature. 1988;331:277
  17. Ben-David Y, Giddens EB, Letwin K, Bernstein A. Erythroleukemia induction by Friend murine leukemia virus: insertional activation of a new member of the ETS gene family, Fli-1, closely linked to C-ETS-1. Genes Dev. 1991;5:908
  18. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265:1573
  19. Bories JC, Willerford DM, Grevin D, Davidson L, Camus A, Martin P, et al.  Increased T cell apoptosis and terminal B cell differentiation induced by inactivation of the ETS-1 proto-oncogene. Nature. 1995;377:635
  20. Muthusamy N, Barton K, Leiden JM. Defective activation and survival of T cells lacking the ETS-1 transcription factor. Nature. 1995;377:639
  21. Leiden JM, Wang CY, Petryniak B, Markovitz DM, Nabel GJ, Thompson CB. A novel ETS-related transcription factor, ELF-1, binds to human immunodeficiency virus type 2 regulatory elements that are required for inducible transactivation in T cells. J. Virol. 1992;66:5890
  22. Gottschalk LR, Giannola DM, Emerson SG. Molecular regulation of the human IL-3 gene: inducible T cell-restricted expression requires intact AP-1 and ELF-1 nuclear protein binding sites. J. Exp. Med. 1993;178:1681
  23. John S, Reeves RB, Lin JX, Child R, Leiden JM, Thompson CB, et al.  Regulation of cell-type-specific interleukin-2 receptor alpha-chain gene expression: potential role of physical interactions between ELF-1, HMG-I (Y), and NF-kappa B family proteins. Mol. Cell. Biol. 1995;15:1786
  24. Wang CY, Bassuk AG, Boise LH, Thompson CB, Bravo R, Leiden JM. Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of ELF-1 and AP-1 transcription factors. Mol. Cell. Biol. 1994;14:1153
  25. Wurster AL, Siu G, Leiden JM, Hedrick SM. ELF-1 binds to a critical element in a second CD4 enhancer. Mol. Cell. Biol. 1994;14:6452; [published erratum appears in Mol. Cell. Biol. 1994;14;8493]
  26. Markovitz DM, Smith MJ, Hilfinger J, Hannibal MC, Petryniak B, Nabel GJ. Activation of the human immunodeficiency virus type-2 enhancer is dependent on purine box and kappa B regulatory element. J. Viol. 1992;66:5479
  27. Hilfinger JM, Clark N, Smith M, Robinson K, Markovitz DM. Differentiation regulation of the human immunodeficiency virus type 2 enhancer in monocytes at various stages of differentiation. J. Viol. 1993;67:4448
  28. Miyazaki Y, Sun X, Uchida H, Nimer S. MEF, a novel transcription factor with an ELF-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene. 1996;13:1721
  29. Oettgen P, Akbarali Y, Boltax J, Best J, Kunsch C, Libermann TA. Characterization of NERF, a novel transcription factor related to the ETS factor ELF-1. Mol. Cell. Biol. 1996;16:5091
  30. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann. Intern. Med. 1985;103:620
  31. Cheng T, Shen H, Giokas D, Tenen DG, Scadden DT. Temporal mapping of gene expression levels during the differentiation of individual primary hematopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 1996;93:13158
  32. Okuda T, van Deursen J, Heibert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemias, is essential for normal fetal liver hematopoiesis. Cell. 1996;4:321
  33. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 1995;86:1
  34. Mao S, Frank RC, Zhan J, Miyazaki Y, Nimer SD. Functional and physical interaction between AML1 proteins and an ETS protein, MEF: implication for the pathogenesis of t(8;21)-positive leukemias. Mol. Cell. Biol. 1999;19:3635

PII: S0145-2126(02)00214-X

doi: 10.1016/S0145-2126(02)00214-X

Leukemia Research
Volume 27, Issue 5 , Pages 387-392 , May 2003

Article Tools

* Image Usage & Resolution